Exactly this. Uplisting means nothing until we have a product ready to market, presumably a therapeutic for s/c covid, maybe by February. I think the evidence in support of Leronlimab will build as we approach the next readout and that confidence will buoy the share price enough to facilitate the uplist.
News 
Market Data 
Discover 
AI
